Clinical Trial Pipeline Tracker

研报英文原文证据摘录

Clinical Trial Pipeline Tracker

UpdateM

Upsized/Downsized

Exhibit 9: Trials with increased estimated patient recruitment

Primary Previous Est.

Company Drug Stage Event/Study title Status Est. Size Identifier

Completion Size

Arrowhead ARO-ATXN2 Study of ARO-ATXN2 Injection in Adults With Active, not

Phase1 Dec-26 39 36 NCT06672445

Pharmaceuticals Injection Spinocerebellar Ataxia Type 2 recruiting

A Study of BGB-16673 Compared to Investigator's

BGB-

Choice in Participants With Relapsed/Refractory

16673|Bendamust Active, not

Beone Medicines Phase3 Chronic Lymphocytic Leukemia or Small Lymphocytic Nov-29 153 150 NCT06970743

ine|Rituximab|Me recruiting

Lymphoma Previously Exposed to Covalent Bruton

thylprednisolone

Tyrosine Kinase (BTK) Inhibitors

A Study to Learn More About the Long-Term Safety

and Effects of Felzartamab Infusions in Adults With

Enrolling by

Biogen Felzartamab Phase3 Kidney Transplants Who Have Antibody-Mediated May-31 201 120 NCT07444489

invitation

Rejection (AMR) or Microvascular Inflammation (MVI)

(TRANSCEND/TRANSPIRE LTE)

Safety and Bioactivity of Ipilimumab and Nivolumab

Ipilimumab|Nivolu

Bristol-Myers Squibb Phase1|Phase2 Combination Prior to Liver Resection in Hepatocellular Mar-26 Completed 33 32 NCT03682276

mab

Carcinoma

ELEMENT-MDS: A Study to Compare the Efficacy and

Luspatercept|Epo Safety of Luspatercept in Participants With Active, not

Bristol-Myers Squibb Phase3 Mar-28 402 360 NCT05949684

etin Alfa Myelodysplastic Syndrome (MDS) and Anemia Not recruiting

Receiving Blood Transfusions

Xanomeline/Trospi

A Phase 3 Study to Evaluate the Safety and Efficacy of

um Chloride

Bristol-Myers Squibb Phase3 KarXT + KarX-EC for the Treatment of Agitation Nov-28 Recruiting 426 352 NCT07011732

Capsule|Xanomeli

Associated With Alzheimer's Disease (ADAGIO-1)